<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163643</url>
  </required_header>
  <id_info>
    <org_study_id>637</org_study_id>
    <nct_id>NCT01163643</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome</brief_title>
  <official_title>A Randomized, Double-Masked, Parallel-Group, Vehicle Controlled, Multicenter, Exploratory Study Assessing the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to identify the concentration and daily dosing frequency of&#xD;
      BOL-303242-X ophthalmic suspension in treating dry eye syndrome over a 12 week dosing period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Corneal Staining Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total corneal staining score was calculated by adding the individual grades from 5 regions of the corneal surface (1: Central; 2: Superior; 3: Temporal; 4: Nasal; 5: Inferior). Grade 0 = none and Grade 3 = severe. The minimum total score possible was 0 and the maximum total score possible was 15. Higher scores indicated worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Worst Visual Analog Scale(VAS) Dry Eye Symptom</measure>
    <time_frame>12 weeks</time_frame>
    <description>Each symptom (ocular discomfort, dryness, grittiness, and stinging) was assessed to the nearest millimeter on a 0 - 10 cm Visual Analog Scale (VAS) by the subject. The worst VAS dry eye symptom was utilized in the analysis. The minimum for the worst symptom was 0 and the maximum for the worst symptom was 10.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">356</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>0.3% BOL-303242-X ophthalmic suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3% BOL-303242-X ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2% BOL-303242-X ophthalmic suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% BOL-303242-X ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% BOL-303242-X ophthalmic suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% BOL-303242-X ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2% BOL-303242-X ophthalmic suspension in the morning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2% BOL-303242-X ophthalmic suspension PM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% BOL-303242-X ophthalmic suspension</intervention_name>
    <description>0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
    <arm_group_label>0.3% BOL-303242-X ophthalmic suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% BOL-303242-X ophthalmic suspension</intervention_name>
    <description>2% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
    <arm_group_label>2% BOL-303242-X ophthalmic suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator: Vehicle</intervention_name>
    <description>Placebo Comparator: Vehicle BID for 12 weeks.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% BOL-303242-X ophthalmic suspension</intervention_name>
    <description>1% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
    <arm_group_label>1% BOL-303242-X ophthalmic suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% BOL-303242-X ophthalmic suspension AM</intervention_name>
    <description>2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.</description>
    <arm_group_label>2% BOL-303242-X ophthalmic suspension in the morning</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% BOL-303242-X ophthalmic suspension PM</intervention_name>
    <description>Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.</description>
    <arm_group_label>2% BOL-303242-X ophthalmic suspension PM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who have a diagnosis of dry eye disease.&#xD;
&#xD;
          -  Intraocular pressure (IOP) â‰¤28 mmHg with no IOP lowering medications.&#xD;
&#xD;
          -  Subjects who are willing and able to refrain from using contact lenses during the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with known hypersensitivity or contraindication to any component of the study&#xD;
             medication.&#xD;
&#xD;
          -  Subjects who are expected to require concurrent treatment with ophthalmic medications&#xD;
             (prescription or over the counter).&#xD;
&#xD;
          -  Subjects who are expected to require treatment with corticosteroids during the study.&#xD;
&#xD;
          -  Subjects who have used topical or systemic isotretinoin, cyclosporine, or retinoid&#xD;
             therapies within 30 days prior to the screening visit.&#xD;
&#xD;
          -  Subjects who have undergone any type of ocular surgery within three months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Lacrimal punctal occlusion (plugs or cautery) within 2 months of Screening Visit.&#xD;
&#xD;
          -  Subjects with a history or presence of chronic generalized systemic or ocular disease&#xD;
             that the Investigator feels might increase the risk to the subject or confound the&#xD;
             result of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuyen Ong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <results_first_submitted>August 18, 2020</results_first_submitted>
  <results_first_submitted_qc>August 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 3, 2020</results_first_posted>
  <disposition_first_submitted>March 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 3, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 7, 2012</disposition_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2% BOL-303242-X Ophthalmic Suspension</title>
          <description>2% BOL-303242-X ophthalmic suspension&#xD;
2% BOL-303242-X ophthalmic suspension: 2% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>2% BOL-303242-X Ophthalmic Suspension in the Morning</title>
          <description>2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)&#xD;
2% BOL-303242-X ophthalmic suspension AM: 2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>2% BOL-303242-X Ophthalmic Suspension PM</title>
          <description>Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.&#xD;
2% BOL-303242-X ophthalmic suspension PM: Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>1% BOL-303242-X Ophthalmic Suspension</title>
          <description>1% BOL-303242-X ophthalmic suspension&#xD;
1% BOL-303242-X ophthalmic suspension: 1% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>0.3% BOL-303242-X Ophthalmic Suspension</title>
          <description>0.3% BOL-303242-X ophthalmic suspension&#xD;
0.3% BOL-303242-X ophthalmic suspension: 0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Vehicle</title>
          <description>Vehicle twice daily (BID)&#xD;
Placebo Comparator: Vehicle: Placebo Comparator: Vehicle BID for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="74"/>
                <participants group_id="P5" count="69"/>
                <participants group_id="P6" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="69"/>
                <participants group_id="P5" count="61"/>
                <participants group_id="P6" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2% BOL-303242-X Ophthalmic Suspension</title>
          <description>2% BOL-303242-X ophthalmic suspension&#xD;
2% BOL-303242-X ophthalmic suspension: 2% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>2% BOL-303242-X Ophthalmic Suspension in the Morning</title>
          <description>2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)&#xD;
2% BOL-303242-X ophthalmic suspension AM: 2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>2% BOL-303242-X Ophthalmic Suspension PM</title>
          <description>Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.&#xD;
2% BOL-303242-X ophthalmic suspension PM: Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>1% BOL-303242-X Ophthalmic Suspension</title>
          <description>1% BOL-303242-X ophthalmic suspension&#xD;
1% BOL-303242-X ophthalmic suspension: 1% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>0.3% BOL-303242-X Ophthalmic Suspension</title>
          <description>0.3% BOL-303242-X ophthalmic suspension&#xD;
0.3% BOL-303242-X ophthalmic suspension: 0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Vehicle</title>
          <description>Vehicle twice daily (BID)&#xD;
Placebo Comparator: Vehicle: Placebo Comparator: Vehicle BID for 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="74"/>
            <count group_id="B5" value="69"/>
            <count group_id="B6" value="73"/>
            <count group_id="B7" value="356"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.6" spread="17.79"/>
                    <measurement group_id="B2" value="50.6" spread="16.99"/>
                    <measurement group_id="B3" value="51.8" spread="18.10"/>
                    <measurement group_id="B4" value="46.3" spread="17.64"/>
                    <measurement group_id="B5" value="46.5" spread="15.91"/>
                    <measurement group_id="B6" value="49.5" spread="17.56"/>
                    <measurement group_id="B7" value="48.4" spread="17.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="50"/>
                    <measurement group_id="B7" value="242"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Corneal Staining Score</title>
        <description>Total corneal staining score was calculated by adding the individual grades from 5 regions of the corneal surface (1: Central; 2: Superior; 3: Temporal; 4: Nasal; 5: Inferior). Grade 0 = none and Grade 3 = severe. The minimum total score possible was 0 and the maximum total score possible was 15. Higher scores indicated worse outcome.</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized participants with Week 12 results were included, with no imputation of missing data at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>2% BOL-303242-X Ophthalmic Suspension</title>
            <description>2% BOL-303242-X ophthalmic suspension&#xD;
2% BOL-303242-X ophthalmic suspension: 2% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2% BOL-303242-X Ophthalmic Suspension in the Morning</title>
            <description>2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)&#xD;
2% BOL-303242-X ophthalmic suspension AM: 2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% BOL-303242-X Ophthalmic Suspension PM</title>
            <description>Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.&#xD;
2% BOL-303242-X ophthalmic suspension PM: Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>1% BOL-303242-X Ophthalmic Suspension</title>
            <description>1% BOL-303242-X ophthalmic suspension&#xD;
1% BOL-303242-X ophthalmic suspension: 1% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>0.3% BOL-303242-X Ophthalmic Suspension</title>
            <description>0.3% BOL-303242-X ophthalmic suspension&#xD;
0.3% BOL-303242-X ophthalmic suspension: 0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle</title>
            <description>Vehicle twice daily (BID)&#xD;
Placebo Comparator: Vehicle: Placebo Comparator: Vehicle BID for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corneal Staining Score</title>
          <description>Total corneal staining score was calculated by adding the individual grades from 5 regions of the corneal surface (1: Central; 2: Superior; 3: Temporal; 4: Nasal; 5: Inferior). Grade 0 = none and Grade 3 = severe. The minimum total score possible was 0 and the maximum total score possible was 15. Higher scores indicated worse outcome.</description>
          <population>Randomized participants with Week 12 results were included, with no imputation of missing data at Week 12.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="3.19"/>
                    <measurement group_id="O2" value="3.9" spread="3.87"/>
                    <measurement group_id="O3" value="3.9" spread="3.66"/>
                    <measurement group_id="O4" value="4.4" spread="3.53"/>
                    <measurement group_id="O5" value="4.1" spread="3.03"/>
                    <measurement group_id="O6" value="3.7" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Worst Visual Analog Scale(VAS) Dry Eye Symptom</title>
        <description>Each symptom (ocular discomfort, dryness, grittiness, and stinging) was assessed to the nearest millimeter on a 0 - 10 cm Visual Analog Scale (VAS) by the subject. The worst VAS dry eye symptom was utilized in the analysis. The minimum for the worst symptom was 0 and the maximum for the worst symptom was 10.</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized participants with Week 12 results were included, with no imputation of missing data at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>2% BOL-303242-X Ophthalmic Suspension</title>
            <description>2% BOL-303242-X ophthalmic suspension&#xD;
2% BOL-303242-X ophthalmic suspension: 2% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2% BOL-303242-X Ophthalmic Suspension in the Morning</title>
            <description>2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)&#xD;
2% BOL-303242-X ophthalmic suspension AM: 2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% BOL-303242-X Ophthalmic Suspension PM</title>
            <description>Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.&#xD;
2% BOL-303242-X ophthalmic suspension PM: Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>1% BOL-303242-X Ophthalmic Suspension</title>
            <description>1% BOL-303242-X ophthalmic suspension&#xD;
1% BOL-303242-X ophthalmic suspension: 1% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>0.3% BOL-303242-X Ophthalmic Suspension</title>
            <description>0.3% BOL-303242-X ophthalmic suspension&#xD;
0.3% BOL-303242-X ophthalmic suspension: 0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle</title>
            <description>Vehicle twice daily (BID)&#xD;
Placebo Comparator: Vehicle: Placebo Comparator: Vehicle BID for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Worst Visual Analog Scale(VAS) Dry Eye Symptom</title>
          <description>Each symptom (ocular discomfort, dryness, grittiness, and stinging) was assessed to the nearest millimeter on a 0 - 10 cm Visual Analog Scale (VAS) by the subject. The worst VAS dry eye symptom was utilized in the analysis. The minimum for the worst symptom was 0 and the maximum for the worst symptom was 10.</description>
          <population>Randomized participants with Week 12 results were included, with no imputation of missing data at Week 12.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.256" spread="2.3172"/>
                    <measurement group_id="O2" value="2.954" spread="2.4688"/>
                    <measurement group_id="O3" value="2.290" spread="2.4885"/>
                    <measurement group_id="O4" value="2.407" spread="2.6070"/>
                    <measurement group_id="O5" value="2.535" spread="2.5565"/>
                    <measurement group_id="O6" value="2.026" spread="2.1849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>The safety population included participants who received at least 1 dose of study drug. Participants confirmed to have never took a dose of study drug were excluded from safety analyses. Of the randomized participants, there was one 2% BOL-303242-X Ophthalmic Suspension participant, one 2% BOL-303242-X Ophthalmic Suspension PM participant, one 1% BOL-303242-X Ophthalmic Suspension participant, and 2 Vehicle participants who did not take at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>2% BOL-303242-X Ophthalmic Suspension</title>
          <description>2% BOL-303242-X ophthalmic suspension&#xD;
2% BOL-303242-X ophthalmic suspension: 2% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>2% BOL-303242-X Ophthalmic Suspension in the Morning</title>
          <description>2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)&#xD;
2% BOL-303242-X ophthalmic suspension AM: 2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>2% BOL-303242-X Ophthalmic Suspension PM</title>
          <description>Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.&#xD;
2% BOL-303242-X ophthalmic suspension PM: Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>1% BOL-303242-X Ophthalmic Suspension</title>
          <description>1% BOL-303242-X ophthalmic suspension&#xD;
1% BOL-303242-X ophthalmic suspension: 1% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>0.3% BOL-303242-X Ophthalmic Suspension</title>
          <description>0.3% BOL-303242-X ophthalmic suspension&#xD;
0.3% BOL-303242-X ophthalmic suspension: 0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Vehicle</title>
          <description>Vehicle twice daily (BID)&#xD;
Placebo Comparator: Vehicle: Placebo Comparator: Vehicle BID for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <email>susan.harris@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

